

DE 06-JAN-1999 (first entry)
 DE CDNA sequence of prostate tumour clone P20.
 DE Prostate; cancer; tumour; vaccine; immunogen; clone; ss.
 DE Homo sapiens.
 PN WO98093-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998; US-03492.
 PR 09-FEB-1998; US-020956.
 PR 25-FEB-1997; US-80609.
 PR 01-AUG-1997; US-04804.
 PA (CORI-) CORIXA CORP.
 PT Dillon DC, Xu J;
 DR WI; 98-609886/51.
 PT Polypeptides comprising immunogenic portions of prostate proteins - used in a vaccine for the treatment of prostate cancer.
 PS Claim 3; Page 53-54; 130pp; English.
 CC The present sequence is a new DNA which encodes an immunogenic portion of a prostate tumour protein. The encoded immunogen, or the DNA itself, can be used as a vaccine for the treatment of prostate cancer. The DNA was identified by analysis of a subtracted cDNA library obtained by subtracting a prostate tumour cDNA expression library with a normal tissue cDNA library.
 CC Sequence 234 BP; 43 A; 68 C; 68 G; 55 T;
 SQ

Query Match 100.0%; Score 234; DB 1; Length 234;
 Best Local Similarity 100.0%; Pred. No. 2; 4e-61; Mismatches 0; Indels 0; Gaps 0; Matches 234; Conservative 0; MisMatches 0; Indels 0; Gaps 0

QY 1 acaaacagacccgtgtcgtaaagacccatgtccatcaagtggccatccgtgtcc 60
 DB 1 ACRACAGACCCGTGTGGCTAACGACCCATGTCATCAAGTGGCCATCGTGTCC 60
 QY 61 agtcgtacacccatccggaggatcggatccatgtttgttcggactgtggccatccggggaaacttt 120
 DB 61 AGTCGTACACCCATCCGGAGCATCAGCATGTCATGTCAGTGGCCATCCGGGGAACTTT 120
 QY 121 gctctcggttctgggtggctgtggggacggcggaaatgtggcttacccgtgtggcggactgtgg 180
 DB 121 GCCTCGTCTGGCTGGGCTGCTGGCCGACGGCAGATGCTTACCGGGGAACTTT 180
 QY 181 tgaacgtgtgggtgtcgaggatctggcggaggctcgccatggaaatgtggctgtgg 234
 DB 181 TGAACGTGTGGGTGTGGAGGAGTGTGAGTANGCTCTATGACCCGCTGT 234

RESULT 4 3

1 V58644 standard; cDNA; 1248 BP.
 AC V58644;
 DT 08-DEC-1998 (first entry)
 DE Prostate tumour specific gene clone DE1.
 KW Prostate tumour specific gene; human; prostate cancer; detection; therapy; ss.
 KW Homo sapiens.
 FH Location/Qualifiers
 Key 217. .696
 FT CDS /*tag= a
 FT
 PN WO9837418-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998; US-03490.
 PR 09-FEB-1998; US-904809.
 PR 25-FEB-1997; US-80659.
 PR 01-AUG-1997; US-04809.
 PA (CORI-) CORIXA CORP.
 PI Dillon DC, Xu J;
 DR WI; 98-4480805/41.
 PR P-PSDB; W69387.
 PT Novel human prostate specific tumour protein and fragments - useful for detecting and treating prostate cancers
 Claim 1; Page 112; 141pp; English.
 CC This sequence represents a human prostate tumour specific gene, and can

PR 09-FEB-1998; US-020956.
 PR 25-FEB-1997; US-806059.
 PR 01-AUG-1997; US-904104.
 (CORT-) CORIXA CORP.
 PI Dillon DC, Xu J;
 DR WPI: 98-609886/51.
 PT P-PSDB; W11782.
 PT Polypeptides comprising immunogenic portions of prostate proteins -
 PT used in a vaccine for the treatment of prostate cancer
 PS Claim 3; Page 107; 130pp; English.
 CC The present sequence is a new DNA which encodes an immunogenic portion
 of a prostate tumour protein. The encoded immunogen, or the DNA itself,
 CC can be used as a vaccine for the treatment of prostate cancer. The DNA
 CC was identified by analysis of a subtracted cDNA library obtained by
 CC subtracting a prostate tumour cDNA expression library with a normal
 CC tissue cDNA library.
 SQ Sequence 1167 BP; 242 A; 400 C; 287 G; 222 T;

Query Match 97.8%; Score 228.8; DB 1; Length 1167;
 Local Similarity 98.3%; Pred. No. 1.3e-59; Matches 230; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 acaacagacccgtggctgctacgcgttcatcaaggatggacgaaatccggatcggtccgg 60
 Db 203 ACARAGACRTRCTGCTGCTACGACCTCATGCTCATCAAGTGGACGAAATCGGTCG 262

QY 61 agtctgacaccatccggagactcaggatgttcaggatgttcaggatgttcaggatgttc 120
 Db 263 AGTCTGACACCATCCGGAGCATCAGCATTCGAGTCGGCTACGGGGGAATCTT 322

QY 121 gctcttgcgtggcgggggtctgcggcggacggcggagaatgcttcacgtgtcgatcg 180
 Db 323 GCCTGTGNTCTGGCTGGGTCGTCGGCAAGGGAGATGCCAACGGTCTACCGTCTGG 382

QY 181 tgaacctgtcggtgtgttcaggatgttcaggatgttcaggatgttcaggatgttc 234
 Db 383 TGAACCTGTGTCGGTGTGCTGAGGAGCTCGAGTAACTGATGACCTATGACCCGCTG 436

RESULT 8

ID V37495 standard; DNA: 871 BP.
 AC V37495;
 DT 07-SEP-1998 (first entry)
 DE Human prostate-specific kallikrein (HPSK) encoding DNA.
 KW Prostate-specific kallikrein; HPSK; prostate carcinoma; human;
 KW benign prostate hyperplasia; diagnosis; drug screening; PSK; ss.
 KW Homo sapiens.
 KW Key
 FT Location/Qualifiers
 FT 31. .777
 FT /*tag= a
 FT /transl_except= (pos:367. .369, aa:Xaa)
 FT /transl_except= (pos:412. .414, aa:Xaa)
 FT /product= "HPSK protein"
 FT /note= "Xaa = unknown"
 PD 14-MAY-1998.
 PR 31-OCT-1997; U20051.
 PR 05-NOV-1996; US-744026.
 PA (INCYT-) INCYT PHARM INC.
 PI Bandman O, Goli SK;
 DR WPI: 98-216933/25.
 PT P-PSDB; W60592.
 PT New isolated prostate-specific kallikrein - used to develop products
 PT for diagnosis and treatment of, e.g. prostate carcinoma or benign
 PT hyperplasia.
 PT Fig 1A-C; 65pp; English.
 CC This DNA encodes a human prostate-specific kallikrein (HPSK). A host cell
 CC containing an expression vector comprising the HPSK nucleic acid sequence
 CC can be used to produce the protein recombinantly. The HPSK products can
 CC be used for the diagnosis of conditions or diseases associated with

RESULT 9

ID X1114 standard; cDNA: 402 BP.
 ID X41114 standard; cDNA: 402 BP.
 AC X41114;
 DR 17-JUN-1999 (first entry)
 DE Human secreted protein 5, EST SEQ ID NO: 58.
 KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
 KW forensic; gene therapy; chromosome mapping; signal peptide;
 KW upstream regulatory sequence; cytoline activity; cell proliferation;
 KW differentiation; haemopoiesis regulation; tissue growth regulation;
 KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
 KW thromolytic; anti-inflammatory; tumour inhibition; ds.
 OS Homo sapiens.
 PN W0905548A2.
 PD 11-FEB-1999.
 PR 01-AUG-1997; US-905135.
 PI (GEST-) GENSET.
 PA Ductlet A, Dumas Milne Edwards J, Lacroix B;
 DR WPI: 99-15378/73.
 PT P-PSDB; Y12281.
 PT New nucleic acids encoding human secreted proteins - obtained from
 PT CDNA libraries prepared from e.g. liver, ovary, brain, prostate,
 PT kidney, lung, umbilical cord, placenta and colon tissue
 PR Claim 1; Page 205; 824pp; English.
 PS X41094 to X41347; represent 5 expressed sequence tags (ESTs) for human
 CC secreted proteins, and encode the proteins given in Y12261 to Y12514,
 CC respectively. The proteins given represent the signal peptide and an
 N-terminal fragment of a secreted protein. The nucleic acid sequences
 CC can be used for producing secreted human gene products. They can also
 CC be used to develop products for diagnosis and therapy. The Proteins
 CC obtained may have cytokine activity, cell proliferation/differentiation
 CC activity, haemopoiesis regulating activity, tissue growth regulating
 CC activity, reproductive hormone regulating activity, chemotactic/
 CC chemokinetic activity, haemostatic and thromolytic activity, receptor/
 CC ligand activity, anti-inflammatory activity, tumour inhibition activity
 CC or other activities. The products can be used in forensic, gene therapy
 CC and chromosome mapping procedures. The sequences can also be used for
 CC obtaining corresponding promoter sequences. The nucleic acids encoding
 CC the signal peptide can be used for directing extracellular secretion of
 CC a polypeptide or the insertion of a polypeptide into a membrane, or
 CC importing a polypeptide into a cell.
 SQ Sequence 402 BP; 80 A; 125 C; 121 G; 75 T;

Search completed: June 19, 2000, 18:55:38
Job time: 4033 sec

This Page Blank (uspto)

OM nucleic - nucleic search, using sw model
Run on: June 19, 2000, 18:55:47 ; Search time 94.16 Seconds
(without alignments)
4307.151 Million cell updates/sec

Title: US-09-232-880-107
Perfect score: 1621
Sequence: 1 cggccatggcactgcaggcca.....aaaaaaaaaaaaaaa 1621
Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 311585 seqs, 125096042 residues

Total number of hits satisfying chosen parameters: 623170

Minimum DB seq length: 0
Maximum DB seq length: 1000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : N_Geneseq_36.*

Result No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES					
Result No.	Score	Query	Match Length	DB	ID
1	1621	100.0	1621	1	V58584
2	1621	100.0	1621	1	V61199
3	515	31.8	537	1	V58550
4	515	31.8	537	1	V61180
5	406.6	25.1	773	1	V58481
6	406.6	25.1	773	1	V61141
7	403.2	24.9	793	1	V58510
8	403.2	24.9	793	1	V61276
9	400.2	24.7	816	1	V58480
10	400.2	24.7	816	1	V61140
11	248.2	15.3	1462	1	044447
12	234.8	14.5	5537	1	044448
13	67.8	4.2	2123	1	T59701
14	66.6	4.1	208	1	V09116
15	65.2	4.0	4237	1	V61487
16	63.4	3.9	1172	1	Q58669
17	62.8	3.9	1534	1	T15995
18	62.2	3.8	2094	1	X19489
19	62.2	3.8	2447	1	V54587
20	62	3.8	1474	1	T90174
21	62	3.8	4061	1	V44867
22	61.2	3.8	2594	1	T02367
23	60.8	3.8	270	1	T89602
24	60.8	3.8	1733	1	V81394
25	60	3.7	1220	1	X04311
26	59.8	3.7	2339	1	063892
27	59.8	3.7	1	T01339	
28	59.8	3.7	2634	1	X27062
29	59.6	3.7	1261	1	X04382
30	59.6	3.7	1641	1	Human interleukin-
31	59.4	3.7	17753	1	Norwalk virus stra
32	59.2	3.7	1	T28255	-survival motor neu
33	59.2	3.7	15560	1	Human survival mot
34	59.2	3.7	1582	1	Human survival mot
35	59.2	3.7	1582	1	T18831

The present sequence is a new DNA which encodes an immunogenic portion of a prostate tumour protein. The encoded immunogen, or the DNA itself can be used as a vaccine for the treatment of prostate cancer. The DNA was identified by analysis of a subtracted cDNA library obtained by subtracting a prostate tumour cDNA expression library with a normal tissue cDNA library.

Query Match 15.3%; Score 248.2; DB 1; Length 1462;
 Best Local Similarity 57.4%; Pred. No. 1.1e-42;
 Matches 511; Conservative 0; Mismatches 368; Indels 12; Gaps 3;

Tue Jun 20 08:41:30 2000

us-09-232-880-107.rng

35	59.2	3.7	1582	1	T28259	Survival motor neu
36	59.2	3.7	2001	1	T59700	PTH-like peptide D
37	59.2	3.7	2427	1	Q04107	Human pro-urokinas
38	58.6	3.6	2233	1	V10120	Human retinoid rec
39	58.6	3.6	2377	1	Q20360	Human pro-urokinas
40	58.6	3.6	6644	1	X33181	Base sequence of t
41	58.6	3.6	7372	1	X33182	Base sequence of t
42	58.6	3.6	7797	1	X33180	Cowpox virus bsr f
43	58.6	3.6	7996	1	X33184	Base sequence of t
44	58	3.6	1536	1	Q94111	mML genomic DNA. T
45	58	3.6	2271	1	V84632	Human secreted pro

ALIGNMENTS

RESULT 1
 V58584
 ID V58584 standard; cDNA; 1621 BP.
 AC V58584;
 DT 08-DEC-1998 (first entry)
 DE Prostate tumour specific gene clone F1-12.
 KW Prostate tumour specific gene; human; prostate cancer; detection;
 KW therapy; ss.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT CDS 5..1153
 FT /*tag- a
 PN WO9837418-A2.
 PD 27-AUG-1998.
 PF 25-FEB-1998; U03690.
 PR 09-FEB-1998; US-904809.
 PR 25-FEB-1997; US-806596.
 PR 01-AUG-1997; US-904809.
 PA (CORI-) CORIXA CORP.
 PI Dillon DC, Xu J;
 DR WPI; 98-480805/41.
 DR P-PSDB; W69383.
 PT Novel human prostate specific tumour protein and fragments - useful
 PT for detecting and treating prostate cancers
 PS Claim 1; Page 81-82; 141pp; English.
 CC This sequence represents a human prostate tumour specific gene, and can
 CC be used in the method of the invention. The method is for detecting
 CC prostate cancer comprises contacting a biological sample with an agent
 CC able to bind an immunogenic portion of a prostate protein (such as
 CC encoded by this sequence). An antibody which binds to an immunogenic
 CC portion of the prostate protein, and the method can be used to detect,
 CC monitor progression of, or treat prostate cancers. The antibody may
 CC also be conjugated to a therapeutic agent for use in therapy of prostate
 CC cancers.
 SQ Sequence 1621 BP; 461 A; 330 C; 412 G; 418 T;

Query Match 100.0%; Score 1621; DB 1; Length 1621;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1621; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 cggccatggcactgcaggcatctcggtatggagctgtccggcatggcccccggccgt 60
 |||||
 Db 1 CGCCATGGCACTGCAGGGCATCTCGGTATGGAGCTGTCCGGCTGGCCCCGGCCGT 60
 Qy 61 ctgtgctatggctcggctgacttcggggcgctgtggatcgcgtggaccggccggctc 120
 |||||
 Db 61 CTGTGCTATGGTCTGGCTGACTTCGGGGCGCGTGTGGTACCGCTGGACCCGGCCGGCTC 120
 Qy 121 ccgtacgtggccgttggccggcaagcgctcgatgtgtggaccta 180
 |||||
 Db 121 CCGCTACGACGTGAGCCGCTGGGCCGGCAAGCGCTCGCTAGTGCTGGACCTGAAGCA 180
 Qy 181 gccgcggggagccggctgtcgccgtctgtgcagcggtggatgtgtgtggaccc 240
 |||||
 Db 181 GCCGCGGGGAGCCGCGTGTGGCGTGTGCAAGCGGTGGATGTGCTGGAGCC 240

! This Page Blank (uspto)

This Page Blank (uspto)

This Page Blank (uspto)

This Page Blank (uspto)

PT Polypeptides comprising immunogenic portions of prostate proteins -
PT used in a vaccine for the treatment of prostate cancer
PS Claim 12; Page 61; 130p; English.
CC The present sequence is a DNA which encodes an immunogenic portion
CC of a prostate tumour protein. The encoded immunogen, or the DNA itself
CC can be used as a vaccine for the treatment of prostate cancer. The DNA
CC was identified by analysis of a subtracted cDNA library obtained by
CC subtracting a prostate tumour cDNA expression library with a normal
tissue cDNA library.
SQ Sequence 385 BP; 86 A; 105 C; 94 G; 100 T;

CC or other activities. The products can be used in forensic, gene therapy and chromosome mapping procedures. The sequences can also be used for obtaining corresponding promoter sequences. The nucleic acids encoding the signal peptide can be used for directing extracellular secretion of a polypeptide or the insertion of a polypeptide into a membrane, or importing a polypeptide into a cell.

Query	Match	19.0%	Score	73.2	DB	1	Length	429
Best	Local	Similarity	76.3%	Pred.	No	4.4e-15		
Matches	90	Conservative	0	Mismatches	28	Indels	0	Gaps
Qy	240	gtctggcagtcgtgcataatgagatggggctgtgatccacactcctttagtgtct	299					
Db	51	gcAGGGCCTCTGGCCATAAGTGGGGATGGCTGGACCTGGACCCCTGGCAGCTG	110					
Qy	300	gtcttcacaggccaggctggccacactgtttacaggactcttccatgtccca	357					
Db	111	gcttcgtccaggctccaggtraccacactcttgcgtgcacccgttgcgttgc	168					

X40340 ID X40340 standard; cDNA: 429 BP.
 AC x40340; EST ID No:127.
 DE Human secreted protein 5; expressed sequence tag; diagnosis;
 KW human; secreted protein; EST; expressed sequence tag; diagnosis;
 KW for human; gene therapy; chromosome mapping; signal peptide;
 upstream regulatory sequence; cytokine activity; cell proliferation;
 differentiation; haematoopoiesis regulation; tissue growth regulation;
 reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
 thrombolytic; anti-inflammatory; tumour inhibition; ds.
 OS Homo sapiens.
 PN WO9906439-A2.
 PD 11-FEB-1999.
 PF 31-JUL-1998; IB1233.
 PR 01-AUG-1997; US-904468.
 PA (GEST) GENSET.
 PI Ducier A, Dumas Milne Edwards J, Lacroix B;
 DR WPI; 99-1570/13.
 DR P-PSDB; Y11622.
 PT New nucleic acids encoding human secreted proteins - obtained from
 PT CDNA libraries derived from liver, lung, large intestine, colon,
 thyroid and pancreas tissue
 PS Claim 1; Page 238-239; 398P5; English.
 X40251 to X40397 represent 5 expressed sequence tags (ESTs) for human
 CC secreted proteins, and encode the proteins given in Y11533 to Y11679,
 CC respectively. The proteins given represent the signal peptide and an
 N-terminal fragment of a secreted protein. The nucleic acid sequences
 CC can be used for producing secreted human gene products. They can also
 CC be used to develop products for diagnosis and therapy. The proteins
 CC obtained may have cytokine activity, cell proliferation/differentiation
 CC activity, haematopoiesis regulating activity, tissue growth regulating
 CC activity, reproductive hormone regulating activity, chemotactic/
 CC chemokinetic activity, haemostatic and thrombolytic activity, receptor/
 CC ligand activity, anti-inflammatory activity, tumour inhibition activity

PT
PT nucleic acids encoding human secreted proteins - obtained from
PT cDNA libraries derived from liver, lung, large intestine, colon,
PT thyroid and pancreas tissue
PS
Claim 1: Page 238-239; 398pp; English.
X01251 to X40397 represent 5' expressed sequence tags (ESTs) for human
secreted proteins, and encode the proteins given in Y11533 to Y11679,
respectively. The proteins given represent the signal peptide and an
N terminal fragment of a secreted protein. The nucleic acid sequences
can be used for producing secreted human gene products. They can also
be used to develop products for diagnosis and therapy. The proteins
obtained may have cytoine activity, cell proliferation/differentiation
activity, haemopoiesis regulating activity, tissue growth regulating
activity, reproductive hormone regulating activity, chemotactic/
chemokinetic activity, haemostatic and thrombolytic activity, receptor/
ligand activity, anti-inflammatory activity, tumour inhibition activity
or other activities. The products can be used in forensic, gene therapy
and chromosome mapping procedures. The sequences can also be used for
obtaining corresponding promoter sequences. The nucleic acids encoding
the signal peptide can be used for directing extracellular secretion of
a polypeptide or the insertion of a polypeptide into a membrane, or
importing a polypeptide into a cell.
Sequence 429 BP; 78 A; 132 C; 109 G; 108 T;

Db	100	AGAGGGCTCTAGGTCACACATGCCCAACATTATGGCGAGAAGCCCTGCACTGATCAGG	41	DE Streptococcus pneumoniae genome fragment SEQ ID NO:173.
Oy	110	tctga	114	KW Streptococcus pneumoniae; S. pneumoniae; genome; diagnosis; assay;
ID	078233	standard; DNA; 1336 BP.		KW computer readable medium; vaccine; pharmaceutical composition; ds.
ID	078233;			OS Streptococcus pneumoniae.
Db	40	TCTGA	36	PN W09818931-A2.
RESULT	7			PD 07-MAY-1998.
				PF 31-OCT-1997; U19588.
				PR 31-OCT-1996; US-029160.
				PA (HUMA-) HUMAN GENOME SCI INC.
				PI Barrash SC, Choi GH, Dillon PJ, Dougherty BA, Fannon M,
				PI Kunsch CA, Rosen CA;
				DR WPI; 98-2225/24.
				PT Computer-readable medium with recorded streptococcus pneumoniae
				polynucleotide sequences - useful in diagnostic kits and assays, and
				pharmaceutical compositions and vaccines for Streptococcus
				pneumoniae
				CC Claim 1; Page 1101-1103; 1409PP; English.
				CC The present invention describes a computer readable medium which has
				CC the nucleotide sequences SEQ ID NO:1 to 391 (V52134 to V52524) recorded
				CC on it, or a representative fragment or a sequence at least 95% identical
				CC to SEQ ID NO: 1 to 391. The nucleotide sequences depicted in SEQ ID NO:1
				CC to 391 (V52134 to V52524) are genomic fragments from Streptococcus
				CC pneumoniae. The present invention also describes an isolated nucleic acid
				CC molecule encoding a homologue of any of the fragments of the S. pneumoniae
				CC genome (SEQ ID NO:1 to 391) where the nucleic acid molecule is produced
				CC by a process comprising: (a) screening a genomic DNA library using as a
				CC probe a target sequence defined by any of the sequences in SEQ ID NO:1
				CC to 391, identifying members of the library which contain sequences
				CC that hybridise to the target sequence and isolating the nucleic acid
				CC molecules from the members; or (b) isolating mRNA, DNA or cDNA produced
				CC from an organism, amplifying nucleic acid molecules whose nucleotide
				CC sequence is homologous to amplification primers derived from the
				CC fragment of the S. pneumoniae genome to prime the amplification and
				CC isolating the amplified sequences. The computer readable medium can be
				CC used in a computer-based system for identifying fragments of the
				CC S. pneumoniae genome of commercial importance, or expression modulating
				CC fragments of the S. pneumoniae genome. Products from the present
				CC invention can be used in diagnosis kits and assays, and pharmaceutical
				CC compositions and vaccines for S. pneumoniae.
				SQ Sequence 4185 BP; 1257 A; 992 C; 749 G; 1187 T;
				Query Match
				Best Local Similarity 8.7%; Score 33.4; DB 1; Length 4185;
				Matches 73; Conservative 52.5%; Pred. No. 0; 23; Mismatches 66; Indels 0; Gaps 0;
				Qy 125 tttaaaaaaaggacttgcctaaaaaaggacttgcctggccacgatggctggtagacggatgtgg 184
				Db 1637 TTTTAAATCGGCTTCATCATATAGAAGATACCTTCCTAGTGTAAAGGAGTCTG 1696
				Qy 185 ctgtgtggaggattactttggagaggatctccctgtggatctttagggctgg 244
				Db 1697 CAATGCGGGGTTCTTGTCCAGATCATCTGCAACTGAACCTTGTGATAGA 1756
				Qy 245 gcaatgtggcatacgat 263
				Db 1757 CAAGTGTATCCAGATCGCT 1775
				RESULT 9
				V23127/C
				ID V23127; standard; cDNA; 5053 BP.
				AC V23127;
				DT 14-AUG-1998 (first entry)
				DE cDNA of protein with Rho protein-combining and kinase activity.
				KW Rho protein-binding activity; Protein kinase activity; inhibitor;
				KW smooth muscle fibre formation; smooth muscle contraction;
				KW circulatory disease; treatment; tumour formation; metastasis inhibitor;
				KW autoimmune disease; platelet aggregation inhibitor; ss.
				Bos sp.
				OS
				FH Key
				FT Location/Qualifiers 1..4167
				FT /*tag# a

Tue Jun 20 08:41:42 2000

us-09-232-880-67.rng